OrbiMed-backed Theseus debuts with $100M round in heroic quest for 'pan-variant' kinase inhibitors
Despite the promise of kinase inhibitors in treating rare tumors, narrow therapeutic targets for most candidates can halt efficacy the moment a patient’s tumor cells mutate. Now, an OrbiMed-backed startup will take a nine-figure fundraising round to advance its purposefully broad candidates against treatment-resistant tumors.
Boston-based Theseus Pharmaceuticals has bagged a $100 million Series B round it will use to advance a suite of “pan-variant” tyrosine kinase inhibitors (TKI), including a lead compound targeting KIT-mutant gastrointestinal stromal tumors, the company said Tuesday.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.